A practical reference on 三重激动剂: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Dulgo pole Zefir Bulgarian population #2 Clone 11-6-22 Clone 80-121-33 Mitcham Digne 38 Mitcham Ribecourt 19 'Todd's Mitcham', a verticillium wilt-resistant cultivar produced from a breeding and test program of atomic gardening at Brookhaven National Laboratory from the mid-1950s 'Refined Murray', also verticillium-resistant 'Roberts Mitcham', also verticillium-resistant and also the product of mutation breeding
The Ebers Papyrus is among the oldest and most important medical papyri of Ancient Egypt. Written c. 1550 BC, it was likely copied from a series of much earlier texts, and contains a passage from the First Dynasty (c. 3400 BC). The document is named after Georg Ebers, who purchased the document in 1872 in the city of Luxor, the site of Thebes (known to Ancient Egyptians as Waset). Thebes was the most venerated city of Ancient Egypt in its heyday during the Middle Kingdom and New Kingdom. The Ebers Papyrus is thought to contain the first known medical reference to diabetes, by the phrase: "...to eliminate urine which is too asha". The crucial word asha can mean both "plentiful" and "often". It is unclear whether the condition described was excessive urine (polyuria), which may have been symptomatic of diabetes, or increased frequency of urine, very often due to urinary tract infection. The following mixture was prescribed for treatment: "A measuring glass filled with Water from the Bird pond, Elderberry, Fibres of the asit plant, Fresh Milk, Beer-Swill, Flower of the Cucumber, and Green Dates". Urinary troubles in the adult were also corrected with "rectal injections of olive oil, honey, sweet beer, sea salt, and seeds of the wonderfruit".
Hexamers are characteristic of arthropod hemocyanins. A hemocyanin of the tarantula Eurypelma californicum is made up of 4 hexamers or 24 peptide chains. A hemocyanin from the house centipede Scutigera coleoptrata is made up of 6 hexamers or 36 chains. Horseshoe crabs have an 8-hexamer (i. e. 48-chain) hemocyanin. Simple hexamers are found in the spiny lobster Panulirus interruptus and the isopod Bathynomus giganteus. Peptide chains in crustaceans are about 660 amino acid residues long, and in chelicerates they are about 625. In the large complexes there is a variety of variant chains, all about the same length; pure components do not usually self-assemble.
== Usage and maintenance == Vehicles traveling on ice roads include ordinary automobiles and trucks of various sizes and weights. Standard winter tires are sufficient: in fact cleats and tire chains can damage the road surface. Tire chains may be stored in the vehicle for emergency purposes; they can also come in handy when traveling on a winter road with grades steeper than 8% on over-land segments. Signage may indicate speed limits, for instance a maximum of 25 km/h (16 mph), and spacing between vehicles, for instance 500 m (1,600 ft) for loads more than 12,500 kg (27,600 lb). These restrictions are to decrease the risks of damage to the ice cover, which would compromise its ability to support the weight it has been designed for. Maintenance comprises two main tasks:
Sources: en.wikipedia.org
=== Traditional coloring with three primaries === The first known case of trichromacy coloration (of 3 primaries) can be found in a work on optics by the Belgian thinker Franciscus Aguilonius in 1613, who in his "Opticorum libri sex, philosophis iuxtà ac mathematicis utiles" in Latin (Roughly, Six books of optics: useful to philosophers as well as to mathematicians), graphed the colors flavvus, rvbevs and cærvlevs (yellow, red and blue) giving rise to the intermediate colors avrevs, viridis and pvrpvrevs (orange, green and purple) and their relationship with the extremes albvs and niger (white and black). However, the idea of three primary colors is older, as Aguilonius supported the view known since the Middle Ages that the colors yellow, red, and blue were the basic or "noble" colors from which all others are derived. This model was used for printing by Jacob Christoph Le Blon in 1725 and called it Coloritto or harmony of colouring, stating that the primitive (primary) colors are yellow, red and blue, while the secondary are orange, green and purple, or violet. In 1766, Moses Harris developed an 18-color color wheel based on this model, including a wider range of colors by adding light and dark derivatives.
It is not known how to compensate for the absence of liver function in the long term, although liver dialysis techniques can be used in the short term. Artificial livers have not been developed to promote long-term replacement in the absence of the liver. As of 2018, liver transplantation is the only option for complete liver failure. The liver is the largest internal organ in vertebrates and its structure is similar in all other vertebrates. It is mostly divided into right and left lobes.
methyl Also carbinyl. The alkyl functional group derived from methane, consisting of one carbon atom bonded to three hydrogen atoms, with the chemical formula CH3. It is the simplest hydrocarbon and occurs as a substituent in numerous organic compounds, though it may also exist independently as an ion or radical. In IUPAC nomenclature, the presence of a methyl substituent is indicated with the prefix methyl in the name of the compound, or with the abbreviation Me in chemical formulae; e.g. methyl alcohol (methanol) is often written with the formula CH3OH or MeOH.
This Michaelis–Menten equation is the basis for most single-substrate enzyme kinetics. Two crucial assumptions underlie this equation (apart from the general assumption about the mechanism only involving no intermediate or product inhibition, and there is no allostericity or cooperativity). The first assumption is the so-called quasi-steady-state assumption (or pseudo-steady-state hypothesis), namely that the concentration of the substrate-bound enzyme (and hence also the unbound enzyme) changes much more slowly than those of the product and substrate and thus the change over time of the complex can be set to zero.
=== Reduction to 17% of programs === On March 10, 2025, U.S. Secretary of State Marco Rubio announced that the Trump administration had concluded its review, and 83% of USAID's programs would be cancelled, involving approximately 5,200 contracts.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。